Clinical Report: Evolocumab Reduced CV Events in Diabetes
Overview
Evolocumab significantly reduced the risk of first major cardiovascular events in patients with diabetes and no known significant atherosclerosis. The findings from the VESALIUS-CV trial indicate that aggressive LDL-C lowering can improve cardiovascular outcomes in high-risk populations.
Background
Cardiovascular disease remains a leading cause of morbidity and mortality in patients with diabetes. Effective management of lipid levels, particularly low-density lipoprotein cholesterol (LDL-C), is crucial in reducing cardiovascular risk. The introduction of PCSK-9 inhibitors like evolocumab offers a promising strategy for further lowering LDL-C in patients who do not achieve target levels with statins alone.
Evolocumab reduced the incidence of major cardiovascular events by 2% compared to placebo.
LDL-C levels decreased to a median of 52 mg/dL with evolocumab versus 111 mg/dL with placebo.
Significant reductions in secondary composite outcomes were observed, including a 34% reduction in myocardial infarction.
Cardiovascular death occurred in about 2% of patients receiving evolocumab compared to 3% with placebo.
Results were consistent across various demographic subgroups.
Clinical Implications
The findings support the use of evolocumab in high-risk diabetic patients to achieve lower LDL-C targets and reduce cardiovascular events. Clinicians should consider PCSK-9 inhibitors as an adjunct to statin therapy for patients who do not reach lipid goals.
Conclusion
Evolocumab demonstrates a significant benefit in reducing cardiovascular events in high-risk patients with diabetes, reinforcing the importance of aggressive LDL-C management in this population.
In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.
